Franz B. Humer

Board Director

Director

Allogene Therapeutics, Inc.Allogene Therapeutics, Inc.Citigroup Inc

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 1 saleJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€466k

▼ Sales (2 ops.)

€43k

Latest filing published 09 Dec 2024 for Allogene Therapeutics, Inc., €19k. Read the official filing

Filing timeline

BuySale

Franz B. Humer

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Franz B. Humer: trading record in brief

Filings by Franz B. Humer span 3 companies, the busiest being Citigroup Inc, Allogene Therapeutics, Inc. and Kite Pharma, Inc. Between 1 January 2016 and 5 December 2024, the trades on record add up to 47 filings.

Market trades split into 1 purchase (€466k) and 2 sales (€43k). Purchases outweigh sales by €423k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 41 share grants. 2024 to date brings no purchases and 2 sales.

Most recently, on 9 December 2024, the filings show an open-market sale worth €19k in Allogene Therapeutics, Inc. The last insider purchase was made public on 17 October 2018, 2,925 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.